Vaccines As Alternatives to Antibiotics for Food Producing Animals

Total Page:16

File Type:pdf, Size:1020Kb

Vaccines As Alternatives to Antibiotics for Food Producing Animals Hoelzer et al. Vet Res (2018) 49:64 https://doi.org/10.1186/s13567-018-0560-8 REVIEW Open Access Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs Karin Hoelzer1* , Lisa Bielke2, Damer P. Blake3, Eric Cox4, Simon M. Cutting5, Bert Devriendt4, Elisabeth Erlacher‑Vindel6, Evy Goossens7, Kemal Karaca8, Stephane Lemiere9, Martin Metzner10, Margot Raicek6, Miquel Collell Suriñach11, Nora M. Wong1, Cyril Gay12 and Filip Van Immerseel7 Abstract Vaccines and other alternative products can help minimize the need for antibiotics by preventing and controlling infectious diseases in animal populations, and are central to the future success of animal agriculture. To assess scien‑ tifc advancements related to alternatives to antibiotics and provide actionable strategies to support their develop‑ ment, the United States Department of Agriculture, with support from the World Organisation for Animal Health, organized the second International Symposium on Alternatives to Antibiotics. It focused on six key areas: vaccines; microbial-derived products; non-nutritive phytochemicals; immune-related products; chemicals, enzymes, and innovative drugs; and regulatory pathways to enable the development and licensure of alternatives to antibiotics. This article, part of a two-part series, synthesizes and expands on the expert panel discussions regarding opportuni‑ ties, challenges and needs for the development of vaccines that may reduce the need for use of antibiotics in animals; new approaches and potential solutions will be discussed in part 2 of this series. Vaccines are widely used to prevent infections in food animals. Various studies have demonstrated that their animal agricultural use can lead to signifcant reductions in antibiotic consumption, making them promising alternatives to antibiotics. To be widely used in food producing animals, vaccines have to be safe, efective, easy to use, and cost-efective. Many current vaccines fall short in one or more of these respects. Scientifc advancements may allow many of these limitations to be overcome, but progress is funding-dependent. Research will have to be prioritized to ensure scarce public resources are dedicated to areas of potentially greatest impact frst, and private investments into vaccine development constantly compete with other investment opportunities. Although vaccines have the potential to improve animal health, safeguard agricul‑ tural productivity, and reduce antibiotic consumption and resulting resistance risks, targeted research and develop‑ ment investments and concerted eforts by all afected are needed to realize that potential. Table of Contents 5 Investment decision‑making in the research and devel‑ 1 Introduction opment of veterinary vaccines 2 Vaccines as alternatives to antibiotics 6 Prioritization of diseases for which vaccines can 3 Properties of current vaccines reduce antibiotic use 4 Limitations of current vaccines as alternatives 7 Conclusions to antibiotics References *Correspondence: [email protected] 1 The Pew Charitable Trusts, 901 E Street NW, Washington, DC 20004, USA Full list of author information is available at the end of the article © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat​iveco​mmons​.org/licen​ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat​iveco​mmons​.org/ publi​cdoma​in/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Hoelzer et al. Vet Res (2018) 49:64 Page 2 of 10 1 Introduction were ranked highest for perceived feasibility and among Antibiotic resistance is a global threat to public health [1–4]. the top fve alternative approaches with regard to per‑ Every time an antibiotic is used in any setting, there is a risk ceived efectiveness [10]. A quasi‑experimental study of of selecting for resistant bacterial strains [2, 4–6]. Terefore, farrow‑to‑fnish pig farms in Belgium has demonstrated prudent or judicious antibiotic use is important [7]. In ani‑ the cost‑efectiveness of enhanced biosecurity and vac‑ mal agricultural production, that means using antibiotics cinations to reduce antibiotic consumption [11]. Simi‑ only when absolutely necessary to protect the health of the larly, the implementation of herd‑specifc action plans animal and/or humans, relying on non‑antibiotic alternatives that included improvements in vaccination on pig opera‑ to manage animal health where possible, and making opti‑ tions in Belgium led to reduced antimicrobial consump‑ mal treatment choices with regard to antibiotic drug selec‑ tion and improvements in production parameters such as tion and treatment protocol when antibiotics are needed. mortality rates and daily weight gains [12]. Alternatives to antibiotics can help minimize the need for A variety of studies have demonstrated that the use of antibiotics by helping to prevent and control infectious dis‑ various bacterial as well as viral vaccines in animal popu‑ eases in animal populations. As such, safe and efective lations can result in a signifcant reduction in antibiotic alternatives are crucially important to the future success of consumption [13]. For example, the introduction and animal health and production. To assess scientifc advance‑ widespread routine use of a vaccine against Aeromonas ments in the research and development of alternatives to salmonicida led to a signifcant decrease in antibiotic antibiotics, highlight promising research results and novel use in the farmed salmon industry [14, 15]. Similarly, technologies, assess challenges associated with their com‑ research has demonstrated that vaccination against Law- mercialization and use, and provide actionable strategies to sonia intracellularis, the causative agent of ileitis, in Dan‑ support their development, the United States Department of ish pig herds can reduce oxytetracycline consumption for Agriculture (USDA), with support from the World Organi‑ this condition by almost 80%; vaccination also led to sig‑ sation for Animal Health (OIE), organized the second Inter‑ nifcantly fewer pigs being treated with oxytetracycline, national Symposium on Alternatives to Antibiotics [8]. Te and improved productivity parameters such as aver‑ symposium focused on six key areas: vaccines; microbial‑ age daily gains and carcass weights [16]. Improvements derived products; non‑nutritive phytochemicals; immune‑ in mortality rates, feed conversion ratio, pig uniform‑ related products; chemicals, enzymes, and innovative drugs; ity, the occurrence of clinical diarrhea, and the need for and regulatory pathways to enable the licensure and develop‑ antibiotic treatment after L. intracellularis vaccination ment of alternatives to antibiotics [9]. Tis two‑part manu‑ have also been reported, albeit the efects were in some script synthesizes and expands on the scientifc presentations cases relatively modest and statistical signifcance was and expert panel discussions from the symposium regard‑ not assessed in all of the studies [17–19]. Notably, in one ing the use of vaccines as alternatives to antibiotics that can study on 64 farms in 9 European countries, the majority reduce the need for antibiotic use in animals. Part 1 synthe‑ of pig operations experienced cost reductions for antibi‑ sizes and expands on the expert panel discussions regarding otic treatments after L. intracellularis vaccination, even the opportunities, challenges and needs related to vaccines though not all farms were able to reduce their antibiotic that may reduce the requirement for use of antibiotics in ani‑ use [18]. mals, while part two focuses on highlighting new approaches In a study in Austrian pig herds, vaccination against and potential solutions. Other important factors relevant porcine circovirus type 2 (PCV‑2), a viral infection which to the efective use of vaccines as alternatives to antibiotics, leads to generalized immune suppression and therefore such as educational needs for producers and veterinarians, predisposes animals to secondary bacterial infections, the combination of vaccination strategies with best manage‑ led to a statistically signifcant decrease in antimicrobial ment and husbandry practices, or behavioral aspects related consumption at the farm level, even though the impact to the adoption of vaccination practices are outside the scope varied signifcantly among farm types; while the impact of this manuscript and therefore not discussed here. on fnishing farms was statistically signifcant the decline was negligible on farrow‑to‑fnish farms [20]. Te intro‑ 2 Vaccines as alternatives to antibiotics duction of PCV‑2 vaccination on a Dutch 460 sow farm Vaccines are promising alternatives to antibiotics.1 In a resulted in improvements in average daily gain, mortality recent multi‑country expert‑ranking of alternatives to the rates and decreased antibiotic use (measured as defned use of antimicrobial agents in pig production, vaccines daily doses), assessed based on data spanning 8 months before vaccination, a 4 month transition period, and 1 Alternatives to antibiotics, in this context, are new options and alternative 12 months of routine vaccination [21]. Similarly, intro‑ strategies for the prevention and treatment
Recommended publications
  • Antibody Responses in Furunculosis Patients Vaccinated with Autologous Formalin-Killed S
    Antibody responses in furunculosis patients vaccinated with autologous formalin-killed S. Holtfreter, J. Jursa-Kulesza, H. Masiuk, N. J. Verkaik, C. Vogel, J. Kolata, M. Nowosiad, L. Steil, W. Wamel, A. Belkum, et al. To cite this version: S. Holtfreter, J. Jursa-Kulesza, H. Masiuk, N. J. Verkaik, C. Vogel, et al.. Antibody responses in furunculosis patients vaccinated with autologous formalin-killed. European Journal of Clinical Microbiology and Infectious Diseases, Springer Verlag, 2011, 30 (6), pp.707-717. 10.1007/s10096-010- 1136-3. hal-00690187 HAL Id: hal-00690187 https://hal.archives-ouvertes.fr/hal-00690187 Submitted on 22 Apr 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 Antibody responses in furunculosis patients vaccinated with autologous 2 formalin-killed Staphylococcus aureus 3 4 Silva Holtfreter*1, 1,, Joanna Jursa-Kulesza2, Helena Masiuk2, Nelianne J. Verkaik3, Corne de Vogel3, Julia 5 Kolata1, Monika Nowosiad2, Leif Steil4, Willem van Wamel3, Alex van Belkum3, Uwe Völker4, Stefania 6 Giedrys-Kalemba2, Barbara M. Bröker1 7 8 1 Institute of Immunology and Transfusion Medicine, University of Greifswald, Germany 9 2 Department of Microbiology and Immunology, Pomeranian Medical University, Szczecin, Poland 10 3 Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The 11 Netherlands 12 4 Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald, Germany 13 14 Corresponding author: 15 Dr.
    [Show full text]
  • Antibody Response and Evaluation of Protection After Immunisation With
    Aus dem Institut für Virologie der Tierärztlichen Hochschule Hannover Untersuchungen zur Wirksamkeitsprüfung und praktischen Anwendung von viralen Rinderimpstoffen [Investigations on the efficacy testing and practical application of viral cattle vaccines] Habilitationsschrift zur Erlangung der Venia legendi an der Tierärztlichen Hochschule Hannover Vorgelegt von Dr. med. vet. Birgit Makoschey Hannover 2009 Tag der nichtöffentlichen wissenschaftlichen Aussprache 15. Juni 2010 Table of contents Table of contents Table of contents.....................................................................................................................................3 Abbreviations..........................................................................................................................................4 List of used publications ........................................................................................................................6 A. Introduction...................................................................................................................................8 Vaccines in veterinary medicine.........................................................................................................8 Live attenuated vaccines .................................................................................................................8 Inactivated vaccines ........................................................................................................................9 Alternative approaches
    [Show full text]
  • Vaccination As a Control Tool for Exotic Animal Diseases
    www.defra.gov.uk Vaccination as a Control Tool for Exotic Animal Disease Key Considerations March 2010 Department for Environment, Food and Rural Affairs Nobel House 17 Smith Square London SW1P 3JR Tel: 020 7238 6000 Website: www.defra.gov.uk © Crown copyright 2010 Copyright in the typographical arrangement and design rests with the Crown. This publication (excluding the Royal Arms and departmental logos) may be re-used free of charge in any format or medium for research for non-commercial purposes, private study or for internal circulation within an organisation. This is subject to it being re-used accurately and not used in a misleading context. The material must be acknowledged as Crown copyright and the title of the publication specified. For any other use of this material please apply for a Click-Use PSI Licence or by writing to: Office of Public Sector Information Information Policy Team Kew Richmond Surrey TW9 4DU e-mail: [email protected] Information about this publication and copies are available from: Exotic Disease Policy Programme Defra Nobel House 17 Smith Square London SW1P 3JR This document is available on the Defra website: Published by the Department for Environment, Food and Rural Affairs Vaccination as a Control Tool for Exotic Animal Disease Key Considerations Introduction 4 Using Vaccination against an Exotic Animal Disease: Implications 5 and Considerations Veterinary and Technical Considerations 5 Whether vaccination is the most appropriate disease control tool 5 Box A: A disease for which vaccination is
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,834,015 Oleske Et Al
    USOO5834O15A United States Patent (19) 11 Patent Number: 5,834,015 Oleske et al. (45) Date of Patent: Nov. 10, 1998 54 PROTEIN-LIPID VESICLES AND Charlotte R. Kensil et al, Separation and Characterization of AUTOGENOUS WACCINE COMPRISING THE Saponins with Adjuvant Activity from Quillaia Saponaria SAME Molina Cortex, The Journal of Immunology, vol. 146, pp. 431–437, No. 2, Jan. 15, 1991. 75 Inventors: James M. Oleske, Morris Plains; Jonas E. Salk, M.D. with Mary Contakos et al, Use of Thomas N. Denny, Cranford; Anthony Adjuvants in Studies on Influenza Immunization, J.A.M.A., J. Scolpino, Ramsey; Eleonora vol. 151, No. 14, pp. 1169–1175, Apr. 4, 1953. FeketeoVa, Harrison; Susan Barney S. Graham et al, Augmentation of Human Immuno Gould-Fogerite; Raphael J. Mannino, deficiency Virus Type 1 Neutralizing Antibody by Printing both of Annandale, all of N.J. with gp160 Recombinant Vaccinia and Boosting with 73 Assignees: Albany Medical College, Albany, N.Y.; rgp160 in Vaccinia-Naive Adults, The Journal of Infectious University of Medicine and Dentistry Diseases, 1993, vol. 167, pp. 533–537. of New Jersey, Newark, N.J. E. Celis et al., Regulation of the Human Immune Response to HBSAg: Effects of Antibodies and Antigen Conformation 21 Appl. No.: 712,020 in the Stimulation of Helper T Cells by HBSAg, Hepatology, vol. 5, 744–751, 1985. 22 Filed: Sep. 11, 1996 Jonas Salk, Prospects for the Control of AIDS by Immuniz (51) Int. Cl." ..................................................... A61K 9/127 ing Seropositive Individuals, Nature, vol. 327, Jun. 1987, 52 U.S. Cl. ....................... 424/450; 424/188.1; 424/812; pp.
    [Show full text]
  • Report on Bovine Herpesvirus 1 (BHV1)
    Sanco/C3/AH/R20/2000 EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions &ÃÃ0DQDJHPHQWÃRIÃVFLHQWLILFÃFRPPLWWHHVÃ,,ÃVFLHQWLILFÃFRRSHUDWLRQÃDQGÃQHWZRUNV 5HSRUWRQ %RYLQH+HUSHVYLUXV %+9 PDUNHUYDFFLQHV DQGWKHDFFRPSDQ\LQJ GLDJQRVWLFWHVWV 6FLHQWLILF&RPPLWWHHRQ$QLPDO+HDOWKDQG$QLPDO:HOIDUH $GRSWHG2FWREHU 5HSRUWRQ %RYLQH+HUSHVYLUXV %+9 PDUNHUYDFFLQHVDQGWKH DFFRPSDQ\LQJGLDJQRVWLFWHVWV 6FLHQWLILF&RPPLWWHHRQ$QLPDO+HDOWKDQG$QLPDO:HOIDUH 6&$+$: &RQWHQWV 5(48(67)25$123,1,21 ,1752'8&7,21$1'%$&.*5281' ',6&866,21211(:'$7$210$5.(59$&&,1(6$1'7+(,5,03/,&$7,216)25 %+9(5$',&$7,21 3.1. TYPES OF MARKER VACCINES AND THEIR POSSIBLE USE IN THE EUROPEAN UNION ..........................................3 3.2. EFFICACY OF MARKER VACCINES FOR USE IN ERADICATION PROGRAMMES ......................................................3 ([SHULPHQWDOVWXGLHV )LHOGWULDOV 'LVFXVVLRQDQGFRQFOXVLRQ 3.3 SAFETY, RISKS OF LATENCY, REACTIVATION, RE-EXCRETION, TRANSMISSION AND RECOMBINATION ASSOCIATED WITH THE USE OF LIVE MARKER VACCINES ............................................................................................7 ([SHULPHQWDOVWXGLHV 'LVFXVVLRQDQGFRQFOXVLRQ 3.4. QUALITY OF THE AVAILABLE ACCOMPANYING DIAGNOSTIC TESTS..................................................................9 7HVW6HQVLWLYLW\DQG6SHFLILFLW\ 5HSURGXFLELOLW\ 'LVFXVVLRQ 3.5 POSSIBILITY OF THE EXISTENCE OF SERONEGATIVE CARRIERS AND THE RISKS POSED.....................................11 ([SHULPHQWDOGDWD 'LVFXVVLRQDQGFRQFOXVLRQ *(1(5$/&21&/86,21
    [Show full text]
  • A Review of Fish Vaccine Development Strategies: Conventional Methods and Modern Biotechnological Approaches
    microorganisms Review A Review of Fish Vaccine Development Strategies: Conventional Methods and Modern Biotechnological Approaches Jie Ma 1,2 , Timothy J. Bruce 1,2 , Evan M. Jones 1,2 and Kenneth D. Cain 1,2,* 1 Department of Fish and Wildlife Sciences, College of Natural Resources, University of Idaho, Moscow, ID 83844, USA; [email protected] (J.M.); [email protected] (T.J.B.); [email protected] (E.M.J.) 2 Aquaculture Research Institute, University of Idaho, Moscow, ID 83844, USA * Correspondence: [email protected] Received: 25 October 2019; Accepted: 14 November 2019; Published: 16 November 2019 Abstract: Fish immunization has been carried out for over 50 years and is generally accepted as an effective method for preventing a wide range of bacterial and viral diseases. Vaccination efforts contribute to environmental, social, and economic sustainability in global aquaculture. Most licensed fish vaccines have traditionally been inactivated microorganisms that were formulated with adjuvants and delivered through immersion or injection routes. Live vaccines are more efficacious, as they mimic natural pathogen infection and generate a strong antibody response, thus having a greater potential to be administered via oral or immersion routes. Modern vaccine technology has targeted specific pathogen components, and vaccines developed using such approaches may include subunit, or recombinant, DNA/RNA particle vaccines. These advanced technologies have been developed globally and appear to induce greater levels of immunity than traditional fish vaccines. Advanced technologies have shown great promise for the future of aquaculture vaccines and will provide health benefits and enhanced economic potential for producers. This review describes the use of conventional aquaculture vaccines and provides an overview of current molecular approaches and strategies that are promising for new aquaculture vaccine development.
    [Show full text]
  • A Decade of Research Into Classical Swine Fever
    Blome et al. Vet Res (2017) 48:51 DOI 10.1186/s13567-017-0457-y REVIEW Open Access A decade of research into classical swine fever marker vaccine CP7_E2alf ­(Suvaxyn® CSF Marker): a review of vaccine properties Sandra Blome*, Kerstin Wernike, Ilona Reimann, Patricia König, Claudia Moß and Martin Beer Abstract Due to its impact on animal health and pig industry, classical swine fever (CSF) is still one of the most important viral diseases of pigs. To control the disease, safe and highly efcacious live attenuated vaccines exist for decades. However, until recently, the available live vaccines did not allow a serological marker concept that is essentially important to circumvent long-term trade restrictions. In 2014, a new live attenuated marker vaccine, Suvaxyn­ ® CSF Marker (Zoetis), was licensed by the European Medicines Agency. This vaccine is based on pestivirus chimera “CP7_E2alf” that car- ries the main immunogen of CSF virus “Alfort/187”, glycoprotein E2, in a bovine viral diarrhea virus type 1 backbone (“CP7”). This review summarizes the available data on design, safety, efcacy, marker diagnostics, and its possible integration into control strategies. Table of contents in either endemic situations or in case of large, high- 1 Introduction impact contingencies, safe and highly efcacious live 2 Design and manufacturing attenuated vaccines exist for decades [50]. Te under- lying virus strains (e.g. the C-strain of CSFV or the 3 Genetic stability guinea-pig exaltation negative ­GPE−-strain) were 4 Safety and vaccine virus distribution attenuated through serial passages in either animals 5 Efcacy (rabbits) or cell culture, and have been implemented 6 Diva as part of mandatory control programs that led to the 6.1 Genetic DIVA eradication of CSF from several countries [19].
    [Show full text]
  • Best-Practice Framework for the Use of Vaccines in Animals
    Best-practice framework for the use of vaccines in animals EPRUMA best-practice framework 1 CONTENTS Introduction ................................................................................ 2 About vaccines ........................................................................... 3 Animal vaccination as part of an overall health strategy, prevention plans and responsible use ....................................... 4 Proper vaccination: recommendations.... .................................. 5 Conclusions ................................................................................ 7 INTRODUCTION EPRUMA promotes the responsible use of medicines in animals (www.epruma.eu) and shares information on best practices to prevent, control and treat animal diseases, supporting animal health and welfare, contributing to food safety, and safeguarding human wellbeing and public health. Within EPRUMA best practice guidelines, the and control infectious diseases, vaccination role of vaccination has always been highlighted. improves animal health and reduces the need Through this document, EPRUMA partners for treatment, while contributing to food safety wish to raise awareness on the benefits of and public health. vaccination, and recommend best practices for Nevertheless, the benefits of vaccination vaccine use to ensure optimal animal health. have been questioned recently by anti- vaccine pressure groups. A survey conducted Infectious disease prevention can be achieved among citizens in 2016 showed that 66% of through a combination of measures,
    [Show full text]
  • Elisabeth Erlacher-Vindel, World Organisation for Animal
    Elisabeth Erlacher-Vindel Head of the Antimicrobial Resistance & Veterinary Products Department Prioritization of Vaccines to Reduce Antibiotic use in Animals PACCARB Meeting Washington, 30 January 2019 World Organisation for Animal Health (OIE) 182 Member Countries 301 75 Reference Centres Partner organisations World Organisation for Animal Health 12 Headquarters Regional & Sub-regional Paris Representations “to improve animal health, veterinary public health and animal welfare worldwide” World Organisation for Animal Health · Protecting animals, Preserving our future | 2 OIE ad hoc Groups The OIE convened two ad hoc Groups to provide guidance on prioritisation of diseases for which the use of vaccines could reduce antimicrobial use in animals: • pigs, poultry and fish (April 2015) http://www.oie.int/en/standard-setting/specialists-commissions-working-groups/scientific- commission-reports/ad-hoc-groups-reports/ • cattle, sheep and goats (May 2018) http://www.oie.int/standard-setting/specialists-commissions-working-groups/scientific- commission-reports/ad-hoc-groups-reports/ World Organisation for Animal Health · Protecting animals, Preserving our future | 3 6.1. Key principles adopted In order to facilitate identification of infections where new or improved vaccines would have the maximum potential to reduce antibiotic use, a number of key considerations were agreed and applied: 1. Identification of the most prevalent and important bacterial infections in chickens, swine, and identification of fish species that are commonly farmed and associated with high antibiotic use, and associated prevalent bacterial infections in those species. 2. Identification of common non-bacterial infections in chicken, swine and fish (e.g. protozoal, viral) showing clinical signs that trigger empirical antibiotic treatment (e.g.
    [Show full text]
  • Optimizing Immunity Fin ‘No Antibiotics Ever’ And‘Reduced Use’ Broiler flocks
    POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY Optimizing immunity fin ‘no antibiotics ever’ and‘reduced use’ broiler flocks july 2017 • INDIANAPOlIS, INDIANA P O U - 0 0 0 9 4 POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY Jon Schaeffer, DVM, PHD Director, Poultry Veterinary Services, Zoetis Inc. [email protected] • zoetisus.com/foodsafety WELCOME The growing trend toward “no antibiotics ever” and “reduced use” production systems has prompted poultry companies to rethink their traditional disease-management practices. When flocks are raised with few or no antibiotics, they’re naturally more susceptible to diseases caused by primary or secondary infections. This has presented a huge challenge for poultry veterinarians. alternative therapies have shown potential, but reports from the field — both scientific and anecdotal — show they’ve also been inconsistent. Making refinements in nutrition, stocking rates and housing may help to reduce disease pressure. But in the end, finding ways to optimize immunity and give broilers more “staying power” could be the best strategy for maintaining the health and welfare of these birds. To help the poultry industry meet this goal, we brought together an all-star team of experts with expertise in three diseases affecting the broiler’s immune system — IBD, Marek’s and reovirus — to talk about what producers can do now to raise the bar for protection and flock welfare. This booklet presents highlights from that lively and informative discussion. Special thanks to the participants
    [Show full text]
  • Farm-Vaccine-Long.Pdf
    GUIDELINES Responsible use of vaccines and vaccinations in farm animal production A farm health planning initiative in partnership with DEFRA Supported by the National Office of Animal Health (NOAH) November 2006 CONTENTS Page No. CONTENTS........................................................................................................................1 INTRODUCTION.............................................................................................................. 3 THE MECHANISMS OF INFECTION AND IMMUNITY ......................................... 4 Defence Mechanisms.......................................................................................................... 4 IMMUNITY........................................................................................................................5 Humoral (or [Blood] Circulating) Immunity .................................................................. 6 Cell Mediated Immunity (CMI) ....................................................................................... 7 THE OBJECTIVES OF VACCINATION ...................................................................... 8 TYPES OF ANTIBODY.................................................................................................... 8 THE PROCESS OF PRODUCING AN IMMUNE RESPONSE.................................. 8 Vaccines ............................................................................................................................ 10 Reactivation of the Immune Response..........................................................................
    [Show full text]
  • A Critical Review About Different Vaccines Against Classical Swine Fever Virus and Their Repercussions in Endemic Regions
    Review A Critical Review about Different Vaccines against Classical Swine Fever Virus and Their Repercussions in Endemic Regions Liani Coronado 1, Carmen L. Perera 1, Liliam Rios 2, María T. Frías 1 and Lester J. Pérez 3,*,† 1 National Centre for Animal and Plant Health (CENSA), OIE Collaborating Centre for Disaster Risk Reduction in Animal Health, San José de las Lajas 32700, Cuba; [email protected] (L.C.); [email protected] (C.L.P.); [email protected] (M.T.F.) 2 Reiman Cancer Research Laboratory, Faculty of Medicine, University of New Brunswick, Saint John, NB E2L 4L5, Canada; [email protected] 3 Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Illinois at Urbana–Champaign, Champaign, IL 61802, USA * Correspondence: [email protected] † New Affiliation: Virus Discovery Group, Abbott Diagnostics, Abbott Park, IL 60064, USA. Abstract: Classical swine fever (CSF) is, without any doubt, one of the most devasting viral infec- tious diseases affecting the members of Suidae family, which causes a severe impact on the global economy. The reemergence of CSF virus (CSFV) in several countries in America, Asia, and sporadic outbreaks in Europe, sheds light about the serious concern that a potential global reemergence of this disease represents. The negative aspects related with the application of mass stamping out policies, including elevated costs and ethical issues, point out vaccination as the main control measure against future outbreaks. Hence, it is imperative for the scientific community to continue with the active Citation: Coronado, L.; Perera, C.L.; investigations for more effective vaccines against CSFV.
    [Show full text]